PRIMARY PERITONEAL CARCINOSARCOMA
Clinical trials for PRIMARY PERITONEAL CARCINOSARCOMA explained in plain language.
Never miss a new study
Get alerted when new PRIMARY PERITONEAL CARCINOSARCOMA trials appear
Sign up with your email to follow new studies for PRIMARY PERITONEAL CARCINOSARCOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New vaccine combo shows promise in ovarian cancer fight
Disease control Recruiting nowThis study tests a new treatment for ovarian cancer that has returned after initial therapy. It combines a personalized vaccine made from a patient's own white blood cells (FRαDC) with an immunotherapy drug (pembrolizumab) to help the immune system attack cancer cells. The trial …
Matched conditions: PRIMARY PERITONEAL CARCINOSARCOMA
Phase: PHASE1, PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
New combo therapy aims to control ovarian cancer and reduce painful fluid buildup
Disease control Recruiting nowThis study tests whether adding an experimental drug (APL-2) to standard immunotherapy (pembrolizumab) and/or a targeted therapy (bevacizumab) can better control recurrent ovarian, fallopian tube, or peritoneal cancer that causes fluid buildup in the belly or chest. About 60 adul…
Matched conditions: PRIMARY PERITONEAL CARCINOSARCOMA
Phase: PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New vaccine aims to outsmart ovarian cancer recurrence
Disease control Recruiting nowThis phase II trial tests whether a custom-made vaccine (FRαDCs) can help prevent or delay cancer from coming back in people with stage III or IV ovarian, fallopian tube, or primary peritoneal cancer. The vaccine is made from a patient's own white blood cells and trained to targe…
Matched conditions: PRIMARY PERITONEAL CARCINOSARCOMA
Phase: PHASE2 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 07:52 UTC